Impacto da Ablação por Cateter na FEVE em Pacientes com Fibrilação Atrial e Insuficiência Cardíaca com Fração de Ejeção Reduzida: Uma Revisão Sistemática
Antonio Maria Zacarias Araújo Monteiro, Maria Giovanna da Cruz Tocantins, Jéssica Batista Souza, Renan de Jesus da Silva Albuquerque, João Vitor Ferreira de Oliveira, Roni Oliveira Pinheiro, Ster Marques de Lima Silva, Antonio Maria Zacarias Araújo Monteiro, Maria Giovanna da Cruz Tocantins, Jéssica Batista Souza, Renan de Jesus da Silva Albuquerque, João Vitor Ferreira de Oliveira, Roni Oliveira Pinheiro, Ster Marques de Lima Silva · 2026
Read Impacto da Ablação por Cateter na FEVE em Pacientes com Fibrilação Atrial e Insuficiência Cardíaca com Fração de Ejeção Reduzida: Uma Revisão Sistemática by Antonio Maria Zacarias Araújo Monteiro, Maria Giovanna da Cruz Tocantins, Jéssica Batista Souza, Renan de Jesus da Silva Albuquerque, João Vitor Ferreira de Oliveira, Roni Oliveira Pinheiro, Ster Marques de Lima Silva, Antonio Maria Zacarias Araújo Monteiro, Maria Giovanna da Cruz Tocantins, Jéssica Batista Souza, Renan de Jesus da Silva Albuquerque, João Vitor Ferreira de Oliveira, Roni Oliveira Pinheiro, Ster Marques de Lima Silva (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13399039.txt.
Description
Antonio Maria Zacarias Araújo Monteiro and colleagues published a systematic review in 2026 on catheter ablation for people who have both atrial fibrillation and heart failure with reduced ejection fraction. Their central question was whether the procedure raises the left ventricular ejection fraction, a measure of how well the heart pumps, more than drug treatment does.
Following PRISMA guidance, the team searched five databases in March 2025 and kept only randomized trials that compared ablation against medication. The trials showed better ejection fraction after ablation. One trial, CAMERA-MRI, recorded an absolute gain of 18.3 percent at six months, while CASTLE-AF linked ablation to fewer cardiovascular deaths and fewer heart failure hospital stays. The authors pooled no results in a meta-analysis, so they caution that the mixed evidence should be read carefully.
Catalog record
| CREATOR | Antonio Maria Zacarias Araújo Monteiro, Maria Giovanna da Cruz Tocantins, Jéssica Batista Souza, Renan de Jesus da Silva Albuquerque, João Vitor Ferreira de Oliveira, Roni Oliveira Pinheiro, Ster Marques de Lima Silva, Antonio Maria Zacarias Araújo Monteiro, Maria Giovanna da Cruz Tocantins, Jéssica Batista Souza, Renan de Jesus da Silva Albuquerque, João Vitor Ferreira de Oliveira, Roni Oliveira Pinheiro, Ster Marques de Lima Silva |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41897 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |